文献速递白血病

SLIT2在急性髓系白血病模型中调控白血病细胞增殖与基质支持

SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models.
PubMed 文献 · Br J Haematol · 2026-09-24

该研究探讨SLIT2在急性髓系白血病(AML)中的作用,发现AML患者间充质干细胞(MSC)中SLIT2表达下调,且SLIT2蛋白水平高于正常者预后更好。机制上,SLIT2敲低使MSC表达CXCL12和KIT增加并阻止髓系分化,而重组SLIT2抑制AML细胞增殖和克隆形成,并在人源异种移植模型中降低白血病负荷、延缓疾病进展并改善生存。

要点

  • AML患者MSC中SLIT2下调,SLIT2蛋白高于正常者预后更好。
  • SLIT2敲低MSC上调CXCL12和KIT并阻止原代AML细胞髓系分化。
  • 重组SLIT2抑制AML细胞增殖和克隆形成,异种移植中降低负荷并改善生存。

核心结论

  • SLIT2可能作为抑癌因子,其缺失损害髓系终末分化,SLIT2信号可能成为AML潜在治疗轴。

研究设计与样本

  • 研究采用AML患者来源间充质干细胞、原代AML细胞共培养及人源异种移植模型进行功能验证。

主要发现

  • AML患者MSC中SLIT2表达下调,SLIT2蛋白高于正常者预后更好且独立于经典风险因素。
  • MSC中SLIT2敲低上调CXCL12和KIT表达,共培养阻止原代AML细胞髓系分化。
  • 重组SLIT2对所有测试模型中的AML细胞有细胞静止效应,减少增殖和克隆形成。
  • 人源异种移植模型中全身给予重组SLIT2降低骨髓和脾脏白血病负荷、延缓疾病进展并改善生存。

临床怎么用

  • SLIT2信号通路可能作为AML的潜在治疗靶点,重组SLIT2在临床前模型中显示治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukaemia (AML) is supported by leukaemic stem cells (LSCs), whose continued existence and growth are dependent upon signals derived from their bone marrow (BM) microenvironment. Although the highly conserved glycoprotein slit guidance ligand 2 (SLIT2), implicated in axon guidance, has been proposed to support normal haematopoietic stem cell (HSC) function, its role in AML pathogenesis remains poorly defined. Here, we show that SLIT2 is downregulated in mesenchymal stem cells (MSCs) from AML patients. Patients with higher-than-normal SLIT2 protein levels had better outcomes, independently of classical risk factors. Functionally, knocking down (KD) SLIT2 in MSCs caused a reprogramming of the microenvironment. Specifically, SLIT2-KD in MSCs resulted in increased expression of LSC-supporting genes including C-X-C motif chemokne ligand 12 (CXCL12) and KIT proto-oncogene, receptor tyrosine kinase (KIT), and co-culture of primary AML cells on SLIT2-KD stromal cells prevented myeloid differentiation. Conversely, the addition of recombinant SLIT2 had cytostatic effects on AML cells, resulting in reduced proliferation and reduced clonogenicity in all tested models. Furthermore, in human xenograft models, systemic administration of recombinant SLIT2 resulted in a decrease in leukaemic burden in BM and spleen, delayed disease progression and improved survival. Overall, these data demonstrate that SLIT2 may act as a tumour suppressor, while SLIT2 loss impairs myeloid terminal differentiation, suggesting that SLIT2 signalling could serve as a potential therapeutic axis in AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Albuquerque-Simões L, Weinhäuser I, Pereira-Martins DA, et al. SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models. Br J Haematol. 2026. PMID: 42786580. doi:10.1111/bjh.70785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。